The Board of Directors and the Chief Executive Officer of
Six months, January -
- Net sales amounted to
0 SEK (0 SEK ). -
Result after financial items amounted to
-3,641,239 SEK (-2,898,387 SEK ). -
Earnings per share amounted to
-0.23 SEK (-0.38 SEK ). - Equity ratio amounted to 93.7% (92.6%)
Three months, April -
- Net sales amounted to
0 SEK (0 SEK ). -
Result after financial items amounted to
-2,179,986 SEK (-1,123,481 SEK ). -
Earnings per share amounted to
-0.14 SEK (-0.15 SEK ).
Significant events during April -
Alzinova announced in April that the documentation required for the application to start the planned Phase 1b clinical study with the drug candidate ALZ-101 will be ready during June. The study is planned to start during the third quarter, with the first patient first dose (FPFD) administered during third quarter.Anders Blom was elected as a newAlzinova board member in May. Anders brings valuable experience from business and corporate development.
Significant events after the second quarter of 2021
- In July,
Alzinova presented preclinical data on Alzheimer's disease candidates at the Alzheimer'sAssociation International Conference (AAIC). The preclinical data support the continued development ofAlzinova's lead candidate, ALZ-101.
CEO comments
The second quarter has been intensive and very inspiring, and
In May, we received the final ethical approval of the study from the national ethics committee in
Finland .- The documentation required for the application to start the clinical study was finalised and was sent in June to the Finnish regulatory authority, Fimea, for approval to start the study.
- The clinical study material for the Phase 1b study was manufactured and is ready to be delivered ahead of the recruitment of the first patients.
We are now awaiting approval from Fimea to enter the clinical phase, which will be an important milestone for the company. We are very much looking forward to this and it feels extremely gratifying and encouraging to soon be able to treat patients with ALZ -101.
During the summer, the
In July, together with researchers from the
The Phase 1b clinical study that we are about to start with ALZ-101 will be in patients with mild Alzheimer's disease. The study will evaluate the vaccine candidate's tolerability and safety. It will study the immunological response to the vaccine after multiple doses, as well as a number of biomarkers that are associated with Alzheimer's disease.
At the AAIC conference, improved diagnostic tools under development were also presented, including blood biomarkers. This provides hope for early diagnosis of Alzheimer's disease, which in turn creates better opportunities for earlier treatment with a disease-modifying therapy
Besides our focus on ALZ-101 and the start of the clinical study, we have continued the development of our antibody, ALZ-201. We are working to humanise the antibody as a first step to making it our next candidate to be tested in humans.
Our financial situation remains stable and the cost of development for our R&D activities is according to plan. We forecast that our current liquidity, together with the capital we expect to raise in the beginning of next year through the ongoing subscription warrants programmes, will ensure the delivery of the Phase 1b clinical study and the continued development work with ALZ-101. Besides this, we are continuously working to evaluate different financing opportunities with the aim to develop our product portfolio.
The Covid-19 situation seems to be improving inside and outside
I am very proud to see our therapeutic vaccine shortly will enter the clinical phase and I'm looking forward to continue our important work to treat and prevent the onset and progression of Alzheimer's disease.
Our long-term goal to develop a long-acting and effective therapy that enables patients to live an active and independent live without any impact of Alzheimer's disease has now come that little bit closer.
Finally, I would like to warmly welcome our new board member,
Kristina Torfgård, CEO
The full report, which is attached in the press release, can also be downloaded from the company's English website, www.alzinova.com/investors/financial-reports/
For more information, please contact:
Kristina Torfgård, VD
tel: +46 708 46 79 75
E-mail: kristina.torfgard@alzinova.com
Håkan Skogström, CFO
tel: +46 705 85 08 59
E-mail: hakan.skogstrom@alzinova.com
The information was submitted for publication, through the agency of the contact person set out above, at
About
https://news.cision.com/alzinova/r/alzinova-ab-interim-report-january---june-2021,c3403346
https://mb.cision.com/Main/13200/3403346/1459104.pdf
(c) 2021 Cision. All rights reserved., source